Clinical Trials

Carcinoma, Transitional Cell

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 2 FDA

Phase 1 Active not recruiting

Metastatic Urothelial Cancer

NCT04004442 2026-03-13

COAXIN

19 enrolled

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07460245 2026-03-10

AVESEC

144 enrolled

Carcinoma, Transitional Cell

NCT06412848 2026-02-24

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Active not recruiting

360 enrolled

Phase 1 Active not recruiting

Carcinoma, Transitional Cell

NCT03252938 2026-02-19

INSIGHT

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05327530 2026-01-26

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

256 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

9 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Phase 1/2 Terminated

73 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03744793 2026-01-09

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

18 enrolled

Carcinoma, Transitional Cell

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

25 enrolled

Neoplasm Metastasis, Penile Neoplasms

NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Phase 1 Completed

21 enrolled

Carcinoma, Transitional Cell

NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

106 enrolled 36 charts

Urothelial Cancer

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Recruiting

1,220 enrolled

Carcinoma, Renal Cell

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

14 enrolled 14 charts

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

173 enrolled 28 charts

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Neoplasm Metastasis, Prostatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04678362 2025-09-22

TALASUR

Phase 2 Recruiting

50 enrolled

Carcinoma, Transitional Cell

NCT04887831 2025-09-08

PRESERVE3

92 enrolled 24 charts

886 enrolled 37 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Phase 1/2 Withdrawn

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05431777 2025-04-01

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

79 enrolled 20 charts

Carcinoma, Transitional Cell

NCT05650164 2025-03-28

J-DART2

171 enrolled 36 charts

Carcinoma, Renal Cell

NCT06892860 2025-03-25

DISCUS

Phase 2 Recruiting

320 enrolled

Urinary Bladder Neoplasms

NCT03674424 2025-02-26

AURA

Phase 2 Completed

137 enrolled

Non-metastatic Muscle Invasive Bladder Cancer

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Transitional Cell

NCT04682587 2025-01-03

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

481 enrolled 14 charts

Carcinoma, Renal Cell

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

6 enrolled 12 charts

Urinary Bladder Neoplasms

NCT04068831 2024-12-27

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Phase 2 Completed

18 enrolled 9 charts

Phase 1 Active not recruiting

Carcinoma, Renal Cell

NCT03845166 2024-11-19

STELLAR-001

325 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT06424717 2024-09-27

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Phase 2 Withdrawn